Evidence map›Paper›PMID 32717826›Full record

ReviewAntibiotics (Basel, Switzerland)2020

Best

Su Young Kim, Jun-Won Chung

Abstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Insights intoFrontiers in microbiology · 2024
    Pooled it
  6. Pooled it
  7. Trial
  8. Antibiotics (Basel, Switzerland) · 2026
    Review
  9. Article
  10. Molecules (Basel, Switzerland) · 2026
    Review
  11. Eradication rates of Helicobacter pylori regimens and predictors of treatment failure: A multicenter real-world study in Saudi Arabia.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026
    Article
  12. Review
  13. Review
  14. Review
  15. Towards EffectiveInternational journal of molecular sciences · 2025
    Review
  16. New Quipazine Derivatives Active Against Drug-Resistant OncogenicInternational journal of molecular sciences · 2025
    Article
  17. Review
  18. Therapeutic advances and future directions inFrontiers in microbiology · 2025
    Review
  19. TargetingFrontiers in cellular and infection microbiology · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Su Young KimDivison of Gastroenterology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, 20 Ilsan-ro, Wonju 26426, Korea.ORCID 0000-0002-6486-8445
Jun-Won ChungDivison of Gastroenterology, Department of Internal Medicine, Gachon University, Gil Medical Center, 21, Namdong-daero 774beon-gil, Namdong-gu, Incheon 21565, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotic resistance is the major reason for

Indexed as

antibiotic resistanceeradicationHelicobacter pylori

Identifiers

PMID32717826
PMCPMC7459868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.